eMJA: Duration of anticoagulant therapy for venous thromboembolism

Editorials

Duration of anticoagulant therapy for venous thromboembolism

Nina C Raju, Jack Hirsh and John W Eikelboom

MJA 2009; 190 (12): 659-660

The risk of bleeding, as well as patient preferences, must be considered when deciding duration of warfarin therapy

Venous thromboembolism (VTE) affects about 17 000 Australians each year, usually as deep vein thrombosis (DVT) of the legs or pulmonary embolism (PE).1 The sequelae of VTE include death, post-thrombotic syndrome, chronic pulmonary thromboembolic disease and recurrent VTE. Anticoagulation with an oral vitamin K antagonist (warfarin), overlapped for the first 5–7 days with unfractionated heparin, low-molecular-weight heparin or fondaparinux, prevents thrombus progression and reduces the risk of recurrent VTE and death during the acute phase.2,3 When treatment is continued beyond the acute phase, warfarin reduces the risk of recurrent VTE but increases the risk of bleeding and requires frequent laboratory monitoring, which is inconvenient for patients. Thus, decisions regarding the optimal duration of anticoagulant therapy must balance the increased risk and sequelae of recurrent VTE when warfarin is stopped against the risk of bleeding and the inconvenience of continuing treatment.3

NB: If you are registered with the eMJA, your username is the email address you have provided.
If you don't have a login, click here for subscription options. You will be prompted to create an account upon purchase.

AMA members can login using their AMA username and password.
If you don't know your AMA password, please contact the AMA on 02 6270 5400 or membership@ama.com.au, or try to retrieve your password at this address.

The Medical Journal of Australia eMJA

Username:
Password:

Password forgotten? Click here What is my username?